Skip to content
MarketScale
‹ Back to IndustriesHealthcare

DESIGN TRANSFER: A PROCESS NOT A SINGULAR EVENT

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process.

During the product development process, the Research and Development (R&D) team is under a tight deadline. They may not have the necessary resources or take sufficient time to create proper documentation. Team members may need to make decisions quickly without fully considering how they could take proactive steps to ensure design transfer will go more smoothly. Subject matter experts on the team may only focus on critical design decisions required to make the product work, without regard for manufacturing. Let’s take a look at some ways to improve design transfer.

Look at Design Transfer as a Process Rather than a Single Event

Design transfer is an integral part of the product development process, from conception through final manufacture. Highly reliable, cost-efficient medical devices require proper design transfer, and that starts with Design for Manufacturability (DFM) and Design for Manufacturing and Assembly (DFMA). In DFM and DFMA the focus is not only on the design itself, but also on the assembly method, ensuring manufacturing readiness for building Beta units, pre-production clinical units, and the pilot program. When the R&D team considers these factors and performs in-process testing, it can significantly improve product quality and reduce the overall cost of manufacturing.

Using DFMA 

The goal of DFMA is simple: to transfer product design into viable, robust production methods. To succeed, the team must establish and maintain procedures that ensure the device design translates into production specifications, including final test acceptance. The transfer should negate and/or identify remaining risks such as single-sourcing, long lead items, build timelines, and line/tooling capacity.

A Design Ready for Transfer:

  • Can be built reliably using known and proven manufacturing and assembly processes
  • Includes supporting cell/line qualifications through manufacturing validations such as Operational Qualification (OQ) and Performance Qualification (PQ)
  • Specifies and documents any inspection aids, assembly fixtures, and custom tools required for manufacture
  • Confirms completed agency testing and production target hardware meets regulatory requirements such as FDA, UL, and CE
  • Includes a complete product Bill of Material (BOM) that has been fully costed up to the customer Stock Keeping Unit (SKU) level
  • Includes packaging, labeling, and Instructions for Use (IFU)

At Sunrise Labs, we see Design Transfer as an integral process beginning early in the life of a product with many crucial steps for success. Communication between key stakeholders early and often is critical to turn innovative ideas into commercial medical devices.

Read more at sunriselabs.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The healthcare industry faces significant consequences when delayed decision-making occurs. Prompt and efficient action is crucial to prevent adverse impacts on patient care and operational efficiency. Addressing this issue requires a commitment to more agile and informed decision processes.

  • 01Delayed decision-making in healthcare can lead to negative impacts on patient care and operational efficiency.
  • 02Healthcare organizations are encouraged to adopt agile decision-making processes to improve effectiveness.
  • 03Implementing informed and prompt decision-making strategies can mitigate the risks of inefficiencies and poor patient outcomes.

Aug 17, 2026

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

The Centers for Medicare & Medicaid Services (CMS) launched its tech-enabled chronic care pilot program, known as the ACCESS pilot. Despite its initiation, a significant issue persists as patients struggle to find which healthcare providers are participating in the program. Meanwhile, the FDA has authorized 115 AI-based medical devices in 2021.

  • 01CMS has initiated the ACCESS pilot program to enhance chronic care management using technology.
  • 02Patients are facing challenges in identifying healthcare providers involved in the ACCESS pilot.
  • 03In 2021, the FDA authorized 115 AI-based medical devices.

Aug 17, 2026

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

BioNTech has appointed Guido Oelkers, the current CEO of Sobi, as its next chief executive. Oelkers is tasked with advancing BioNTech's oncology pipeline to achieve multiple approved products by 2030.

  • 01BioNTech has selected Guido Oelkers as its new CEO, effective soon.
  • 02Guido Oelkers aims to turn BioNTech's deep oncology pipeline into several approved products by 2030.

Aug 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512